Beam

Verified USD Foundation Launches USDV - A Revolutionary Stablecoin Transparently Pegged To Tokenized US Treasuries

Retrieved on: 
Tuesday, November 14, 2023
Ethereum, Blockchain, NAV, Entrepreneurship, Animoca Brands, OFT, Avalanche, Stargate, Verified, Bitget, Ecosystem, GEORGE, Beam, Treasury, RWA, Partnership, ZK, Decentralized finance, Cryptocurrency

GEORGE TOWN, Cayman Islands, Nov. 14, 2023 /PRNewswire/ -- The Verified USD Foundation has announced the launch of Verified USD (USDV), a community-driven stablecoin fully backed by the unrivaled on-chain transparency and stability of a basket of tokenized US Treasury Bills (T-bills). A native omnichain stablecoin compatible with the ERC-20 standard, each USDV is pegged to the equivalent value of 1 US dollar.

Key Points: 
  • A native omnichain stablecoin compatible with the ERC-20 standard, each USDV is pegged to the equivalent value of 1 US dollar.
  • "USDV represents a major evolution in stablecoin technology," remarked Matthew Commons, President of the Verified USD Foundation.
  • "Unique among stablecoins, USDV enables a collaborative community approach where those who create stablecoin use cases can be an integral part of the stablecoin value creation.
  • The Verified USD Foundation has chosen Matrixport's Short-term Treasury Bill Token (STBT), as its initial underlying reserve asset.

Verified USD Foundation Launches USDV - A Revolutionary Stablecoin Transparently Pegged To Tokenized US Treasuries

Retrieved on: 
Tuesday, November 14, 2023
Ethereum, Blockchain, NAV, Entrepreneurship, Animoca Brands, OFT, Avalanche, Stargate, Verified, Bitget, Ecosystem, GEORGE, Beam, Treasury, RWA, Partnership, ZK, Decentralized finance, Cryptocurrency

GEORGE TOWN, Cayman Islands, Nov. 14, 2023 /PRNewswire/ -- The Verified USD Foundation has announced the launch of Verified USD (USDV), a community-driven stablecoin fully backed by the unrivaled on-chain transparency and stability of a basket of tokenized US Treasury Bills (T-bills). A native omnichain stablecoin compatible with the ERC-20 standard, each USDV is pegged to the equivalent value of 1 US dollar.

Key Points: 
  • A native omnichain stablecoin compatible with the ERC-20 standard, each USDV is pegged to the equivalent value of 1 US dollar.
  • "USDV represents a major evolution in stablecoin technology," remarked Matthew Commons, President of the Verified USD Foundation.
  • "Unique among stablecoins, USDV enables a collaborative community approach where those who create stablecoin use cases can be an integral part of the stablecoin value creation.
  • The Verified USD Foundation has chosen Matrixport's Short-term Treasury Bill Token (STBT), as its initial underlying reserve asset.

Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 8, 2023
Stem cell, FDA, Eli Lilly and Company, IND, Food, SCD, Trial of the century, Hematology, Biotechnology, LNP Media Group, Congress, Business development, G&A, Health, Thalassemia, Liver, Research and development, Sickle cell disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, CD34, Piz, R, Nature, Growth, Cell, Clinical trial, Gene, Partnership, LNP, PCSK9, ESGCT, AAT, Transplant, General Administration of Sport of China, AATD, Stock, GMP, Safety, European Society for Primary Immunodeficiencies, Investment, ANGPTL3, Patient, Drug discovery, Toxicity, Potential future exposure, ESCAPE, Administration, Cardiovascular disease, Pharmaceutical industry, Medical imaging, Vaccine, Lilly, Beam, Verve

CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported third quarter 2023 financial results and provided an update on the business and its clinical and pipeline progress.

Key Points: 
  • Beam anticipates that currently consented patients are sufficient to both fill the sentinel cohort (n=3) and to initiate the expansion cohort.
  • Research & Development (R&D) Expenses: R&D expenses were $100.0 million for the third quarter of 2023, compared to $85.3 million for the third quarter of 2022.
  • General & Administrative (G&A) Expenses: G&A expenses were $25.4 million for the third quarter of 2023, compared to $21.8 million for the third quarter of 2022.
  • Net Loss: Net loss was $96.1 million for the third quarter of 2023, or $1.22 per share, compared to $109.6 million for the third quarter of 2022, or $1.56 per share.

GHOST TEQUILA ANNOUNCES CHRIS PEDDY AS CHIEF MARKETING OFFICER

Retrieved on: 
Wednesday, November 8, 2023
Global Brands Group, A Chance to Make History, CPG, Peddy, Beam, Acquisition, Lesbian Bar Project, Marketing, Partnership, Jim Beam, Night, Ghost, Alexandra, COVID-19, Tequila, Agave, Management, Liquor

BOSTON, Nov. 8, 2023 /PRNewswire/ -- Ghost Tequila, a 100% agave small batch premium spiced Tequila, is proud to announce Chris Peddy, who has over 25 years of branding experience, as their new Chief Marketing Officer.

Key Points: 
  • BOSTON, Nov. 8, 2023 /PRNewswire/ -- Ghost Tequila, a 100% agave small batch premium spiced Tequila, is proud to announce Chris Peddy, who has over 25 years of branding experience, as their new Chief Marketing Officer.
  • Peddy most recently served as Chief Marketing Officer at Mast-Jägermeister, where he was responsible for relaunching an iconic spirits brand to a new generation of consumers.
  • Made in Jalisco, Mexico, Ghost Tequila combines real ghost peppers blended with agave to create a "Perfectly Spicy" experience unlike any other.
  • By adding a hint of ghost pepper to the tequila, it elevates every sip and makes perfectly spicy tequila cocktails.

Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
Science, Apolipoprotein, Primate, FDA, Gene editing, Lilly, United Kingdom, IND, Beam Therapeutics, RNA, Moyamoya disease, Vertex Pharmaceuticals, Frederick, American Heart Association, Host, G&A, Beam, Research and development, Research, R, Mouse, Medicine, Low-density lipoprotein, PCSK9, Blood, General Administration of Sport of China, Safety, ANGPTL3, AHA, Therapy, Administration, ASCVD, Cardiovascular disease, Pharmaceutical industry, Vaccine, Patient, Vertex, Webcast, Verve

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported recent company progress and financial results for the third quarter of 2023.

Key Points: 
  • ET
    BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported recent company progress and financial results for the third quarter of 2023.
  • Verve plans to participate in fireside chats during the following upcoming investor events:
    Cash Position: Verve ended the third quarter of 2023 with $485.2 million in cash, cash equivalents, and marketable securities.
  • Research & Development (R&D) Expenses: R&D expenses were $43.8 million for the third quarter of 2023, compared to $35.2 million for the third quarter of 2022.
  • General & Administrative (G&A) Expenses: G&A expenses were $11.7 million for the third quarter of 2023, compared to $9.6 million for the third quarter of 2022.

Shenandoah Telecommunications Company Reports Third Quarter 2023 Results

Retrieved on: 
Friday, November 3, 2023
Acceleration, Sale, Sprint, Public expenditure, RGU, Beam, EBITDA, Net, Acquisition, Maintenance, Tower, Advertising, Growth, Commercial, Webcast, Depreciation, Capital expenditure, SMB, Rationalization, Shentel, GLO, Mobile phone, Video game, Bookkeeping, Cryptocurrency, Broadband

EDINBURG, Va., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Shenandoah Telecommunications Company (“Shentel”) (Nasdaq: SHEN) announced third quarter 2023 financial and operating results.

Key Points: 
  • EDINBURG, Va., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Shenandoah Telecommunications Company (“Shentel”) (Nasdaq: SHEN) announced third quarter 2023 financial and operating results.
  • Glo Fiber Markets added approximately 4,500 subscribers; 13.9% higher than the third quarter of 2022 and 12.5% higher than the second quarter 2023.
  • Consolidated net income was $1.6 million in the third quarter of 2023, compared with net loss of $2.7 million in the third quarter of 2022.
  • Broadband operating income was $9.3 million in the third quarter of 2023, compared to $4.8 million in the third quarter of 2022.

Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3

Retrieved on: 
Tuesday, October 31, 2023
Gene editing, Lilly, Eli Lilly and Company, Beam Therapeutics, Obesity, Moyamoya disease, Beam, Diabetes, CVD, Medicine, Risk, PCSK9, ANGPTL3, Therapy, Patient, ASCVD, Cardiovascular disease, Pharmaceutical industry, Verve

Lilly has acquired from Beam Therapeutics certain product rights to Verve’s cardiovascular in vivo gene editing programs targeting PCSK9 and ANGPTL3, as well as a third undisclosed cardiovascular disease (CVD) target.

Key Points: 
  • Lilly has acquired from Beam Therapeutics certain product rights to Verve’s cardiovascular in vivo gene editing programs targeting PCSK9 and ANGPTL3, as well as a third undisclosed cardiovascular disease (CVD) target.
  • Verve holds all product rights for the PCSK9 and ANGPTL3 programs outside the United States.
  • Verve is a leader in developing gene editing therapies for cardiovascular disease, and we are pleased to expand our relationship with Verve to develop much needed new treatment options for people with cardiovascular disease.”
    This transaction represents an expansion of the relationship between Verve and Lilly.
  • Previously, in June 2023 , Verve and Lilly had entered into an exclusive research collaboration focused on advancing Verve’s preclinical stage in vivo gene editing program targeting lipoprotein(a).

Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease

Retrieved on: 
Tuesday, October 31, 2023
Lilly, Eli Lilly and Company, Obesity, Biotechnology, Diabetes, Risk, PCSK9, ANGPTL3, Patient, Cardiovascular disease, Pharmaceutical industry, Beam, Verve

CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Eli Lilly and Company (Lilly) has agreed to acquire certain rights under Beam’s amended collaboration and license agreement with Verve Therapeutics, Inc. (Verve), including Beam’s opt-in rights to co-develop and co-commercialize Verve’s base editing programs for cardiovascular disease, which includes programs targeting PCSK9, ANGPTL3 and an undisclosed liver-mediated, cardiovascular target.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Eli Lilly and Company (Lilly) has agreed to acquire certain rights under Beam’s amended collaboration and license agreement with Verve Therapeutics, Inc. (Verve), including Beam’s opt-in rights to co-develop and co-commercialize Verve’s base editing programs for cardiovascular disease, which includes programs targeting PCSK9, ANGPTL3 and an undisclosed liver-mediated, cardiovascular target.
  • Under the terms of the agreement, Beam will receive a $200 million upfront payment and $50 million equity investment.
  • “As the pioneers in base editing, we’ve had a long-standing vision of enabling a wide range of disease-modifying therapies based on precision genome editing.
  • “This agreement expands the scope of Lilly’s ongoing relationship with Verve and gives us exposure to the full breadth of potential with Beam’s base editing platform.

Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT

Retrieved on: 
Wednesday, October 25, 2023
Gene editing, Survival, FDA, Uric acid, DSM-IV codes, IND, Therapy, Glycogen storage disease, Biotechnology, The First Half of My Life, Congress, Liver, Kidney, Systemic administration, G6PC, Mouse, Hypoglycemia, Cell, Risk, Gene, Triglyceride, LNP, ESGCT, Glucose, European Society for Medical Oncology, Patient, Blood, Cholesterol, Coma, Pharmaceutical industry, Vaccine, Medical imaging, Silviculture, Beam

CAMBRIDGE, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported new preclinical data demonstrating the ability of its in vivo drug candidate, BEAM-301, to directly correct the R83C mutation, one of the primary disease-causing mutations of glycogen storage disease type Ia (GSDIa). The data were presented today in an oral presentation titled “A Single, Systemic Administration of BEAM-301 Mitigated Fasting Hypoglycemia One Year after Dosing in a Transgenic Mouse Model of Glycogen Storage Disease Type-Ia” at the 30th Annual European Society of Gene & Cell Therapy (ESGCT) Congress in Brussels.

Key Points: 
  • “GSDIa is a devastating disease that significantly impacts an individual’s quality of life and puts them at consistent risk of hypoglycemia, coma and potentially death.
  • BEAM-301 is a liver-targeting lipid-nanoparticle (LNP) formulation containing base editing reagents optimized to correct the R83C mutation.
  • These findings support the potential of BEAM-301 to directly correct the disease-causing R83C mutation with a single dose.
  • Beam plans to submit a U.S. IND application in the first half of 2024 for authorization to initiate clinical trials of BEAM-301.

Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline

Retrieved on: 
Thursday, October 19, 2023
Stem cell, Science, Hematology, Biotechnology, Health, Workforce, Sickle cell disease, Research, Growth, Partnership, T-ALL, Investment, Patient, ESCAPE, Pharmaceutical industry, Vaccine, Beam

CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced portfolio priorities and plans to streamline its business operations to support potential near-term value drivers and long-term growth. This plan includes cost reduction initiatives that align with the company’s near-term goals, and the anticipated cost savings are expected to extend its revised operating plan into 2026.

Key Points: 
  • This plan includes cost reduction initiatives that align with the company’s near-term goals, and the anticipated cost savings are expected to extend its revised operating plan into 2026.
  • “From the beginning, Beam’s strategy has been to develop base editing technology broadly across a diverse portfolio of programs and delivery modalities, and our science and pipeline continue to progress across the board.
  • “We are grateful for the dedication and innumerable contributions of our impacted colleagues.
  • The company’s hepatitis B virus program will be paused and designated for partnering given the requirement of specialized development and commercial capabilities.